Abstract
With the increased life expectancy in western industrialized countries, the incidence and prevalence of brain diseases dramatically increased. Stroke and a wide spectrum of neuropsychiatric illnesses such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic head injury, and schizophrenia all lead to severe disability. However, targeted effective therapies for treatment of these diseases are lacking. Even more frustrating is the fact that we do not yet clearly understand the basic mechanisms underlying the disease processes in these conditions. We propose a hypothesis of loss of neuronal function via a final common deleterious pathway in this clinically very heterogeneous disease group. This review presents a novel neuroprotective concept for treatment of brain disease: Erythropoietin (EPO). EPO is a natural body-own-protein hormone that has been used for treatment of anemia for more than a decade. The neuroprotective approach using EPO in brain disease represents a totally new frontier. The “Göttingen EPO-stroke trial” represents the first effective use in man of a neuroprotective therapy in an acute brain disease while the experimental EPO therapy to combat cognitive decline in patients with schizophrenia will be introduced as an example of a neuroprotective strategy for a chronic brain disease.
Similar content being viewed by others
REFERENCES
Agnello, D., Bigini, P., Villa, P., Mennini, T., Cerami, A., Brines, M.L., and Ghezzi, P. (2002). Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 952:128–134.
Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., and Lindvall, O. (2002). Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat. Med. 8:963–970.
Aydin, A., Genc, K., Akhisaroglu, M., Yorukoglu, K., Gokmen, N., and Gonullu, E. (2003). Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury. Brain Dev. 25:494–498.
Bernaudin, M., Marti, H.H., Roussel, S., Divoux, D., Nouvelot, A., MacKenzie, E.T., and Petit, E. (1999). A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J. Cereb Blood Flow Metab. 19:643–651.
Bernaudin, M., Nedelec, A.S., Divoux, D., MacKenzie, E.T., Petit, E., and Schumann-Bard, P. (2002). Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J. Cereb Blood Flow Metab. 22:393–403.
Bohlius, J., Langensiepen, S., Schwarzer, G., and Engert, A. (2002). Epoetin in the treatment of malignant disease: A comprehensive meta-analysis. Blood 100:3430A.
Brines, M.L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N.C., Cerami, C., Itri, L.M., and Cerami, A. (2000). Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U.S.A 97:10526–10531.
Cai, Z., Manalo, D.J., Wei, G., Rodriguez, E.R., Fox-Talbot, K., Lu, H., Zweier, J.L., and Semenza, G.L. (2003). Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108:79–85.
Calvillo, L., Latini, R., Kajstura, J., Leri, A., Anversa, P., Ghezzi, P., Salio, M., Cerami, A., and Brines, M. (2003). Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci U.S.A 100:4802–4806.
Campana, W.M., and Myers, R.R. (2001). Erythropoietin and erythropoietin receptors in the peripheral nervous system: Changes after nerve injury. Faseb J. 15:1804–1806.
Carlsson, A. (1988). The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179–186.
Celik, M., Gokmen, N., Erbayraktar, S., Akhisaroglu, M., Konakc, S., Ulukus, C., Genc, S., Genc, K., Sagiroglu, E., Cerami, A., and Brines, M. (2002). Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. U.S.A 99:2258–2263.
Chattopadhyay, A., Choudhury, T.D., Bandyopadhyay, D., and Datta, A.G. (2000). Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem. Pharmacol. 59:419–425.
Chong, Z.Z., Lin, S.H., Kang, J.Q., and Maiese, K. (2003). Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J. Neurosci. Res. 71:659–669.
De Keyser, J., Sulter, G., and Luiten, P.G. (1999). Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing? Trends Neurosci. 22:535–540.
Digicaylioglu, M., and Lipton, S.A. (2001). Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641–647.
Ehrenreich, H., Degner, D., Meller, J., Brines, M., Behe, M., Hasselblatt, M., Woldt, H., Falkai, P., Knerlich, F., Jacob, S., von Ahsen, N., Maier, W., Brück, W., Rüther, E., Cerami, A., Becker, W., and Sirén, A.-L. (2004). Erythropoietin: A candidate compound for neuroprotection in schizophrenia. Mol. Psychiat. 9:42–54.
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.-H., Breiter, N., Jacob, S., Knerlich, F., Bohn, M., Poser, W., Rüther, E., Kochen, M., Gefeller, O., Gleiter, C., Wessel, T.C., De Ryck, M., Itri, L., Prange, H., Cerami, A., Brines, M., and Sirén, A.-L. (2002). Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8:495–505.
Ehrenreich, H., and Sirén, A.-L. (2001). Special issue-editorial: Neuroprotection—what does it mean?—What means do we have? Eur. Arch. Psychiatry Clin. Neurosci. 251:149–151.
Erbayraktar, S., Grasso, G., Sfacteria, A., Xie, Q.W., Coleman, T., Kreilgaard, M., Torup, L., Sager, T., Erbayraktar, Z., Gokmen, N., Yilmaz, O., Ghezzi, P., Villa, P., Fratelli, M., Casagrande, S., Leist, M., Helboe, L., Gerwein, J., Christensen, S., Geist, M.A., Pedersen, L.O., Cerami-Hand, C., Wuerth, J.P., Cerami, A., and Brines, M. (2003). Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U.S.A 100:6741–6746.
Eriksson, P.S., Perfilieva, E., Bjork-Eriksson, T., Alborn, A.M., Nordborg, C., Peterson, D.A., and Gage, F.H. (1998). Neurogenesis in the adult human hippocampus. Nat. Med. 4:1313–1317.
Genc, S., Akhisaroglu, M., Kuralay, F., and Genc, K. (2002). Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci. Lett. 321:73–76.
Genc, S., Kuralay, F., Genc, K., Akhisaroglu, M., Fadiloglu, S., Yorukoglu, K., Fadiloglu, M., and Gure, A. (2001). Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci. Lett. 298:139–141.
Grimm, C., Wenzel, A., Groszer, M., Mayser, H., Seeliger, M., Samardzija, M., Bauer, C., Gassmann, M., and Reme, C.E. (2002). HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat. Med. 8:718–724.
Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., Schneider, D., Diez-Tejedor, E., and Trouillas, P. (1998). Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352:1245–1251.
Haefner, H. (2000). Epidemiology of schizophrenia. A thriving discipline at the turn of the century. Eur. Arch. Psychiatry Clin. Neurosci. 250:271–273.
Herrmann, M., and Ehrenreich, H. (2003). Brain derived proteins as markers of acute stroke: Their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor. Neurol. Neurosci. 21:177–190.
Jelkmann, W. (2000). Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr. Pharm. Biotechnol. 1:11–31.
Junk, A.K., Mammis, A., Savitz, S.I., Singh, M., Roth, S., Malhotra, S., Rosenbaum, P.S., Cerami, A., Brines, M., and Rosenbaum, D.M. (2002). Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 99:10659–10664.
Kawakami, M., Sekiguchi, M., Sato, K., Kozaki, S., and Takahashi, M. (2001). Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J. Biol. Chem. 276:39469–39475.
Kilts, C.D. (2001). The changing roles and targets for animal models of schizophrenia. Biol. Psychiatry 50:845–855.
Knabe, W., Knerlich, F., Washausen, S., Keitymann, T., Sirén, A.-L., Brunnett, G., Kuhn, H.-J., and Ehrenreich, H. (2004). Expression patterns of erythropoietin and its receptor in the developing midbrain. Anat. Embryol. (Berl). 207:503–512.
Koshimura, K., Murakami, Y., Sohmiya, M., Tanaka, J., and Kato, Y. (1999). Effects of erythropoietin on neuronal activity. J. Neurochem. 72:2565–2572.
Kraepelin, E. (1919). Dementia praecox and Paraphrenia, E & S Livingstone, Edinburgh.
Kremen, W.S., Seidman, L.J., Faraone, S.V., and Tsuang, M.T. (2001). Intelligence quotient and neuropsychological profiles in patients with schizophrenia and in normal volunteers. Biol. Psychiatry 50:453–462.
Kuhn, H.G., Palmer, T.D., and Fuchs, E. (2001). Adult neurogenesis: A compensatory mechanism for neuronal damage. Eur. Arch. Psychiatry Clin Neurosci. 251:152–158.
Lewczuk, P., Hasselblatt, M., Kamrowski-Kruck, H., Heyer, A., Unzicker, C., Sirén, A.L., and Ehrenreich, H. (2000). Survival of hippocampal neurons in culture upon hypoxia: Effect of erythropoietin. Neuroreport 11:3485–3488.
Lewis, D.A., and Levitt, P. (2002). Schizophrenia as a disorder of neurodevelopment. Annu Rev. Neurosci. 25:409–432.
Lieberman, J.A. (1999). Is schizophrenia a neurodegenerative disorder? Aclinical and neurobiological perspective. Biol. Psychiatry 46:729–739.
Lipska, B.K., and Weinberger, D.R. (2000). To model a psychiatric disorder in animals: Schizophrenia as a reality test. Neuropsychopharmacology 23:223–239.
Magavi, S.S., Leavitt, B.R., and Macklis, J.D. (2000). Induction of neurogenesis in the neocortex of adult mice. Nature 405:951–955.
Malaspina, D., Goetz, R.R., Friedman, J.H., Kaufmann, C.A., Faraone, S.V., Tsuang, M., Cloninger, C.R., Nurnberger, J.I., Jr., and Blehar, M.C. (2001). Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees. Am.J.Psychiatry 158:440–446.
Marenco, S., and Weinberger, D.R. (2000). The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave. Dev. Psychopathol. 12:501–527.
Marti, H.H., Wenger, R.H., Rivas, L.A., Straumann, U., Digicaylioglu, M., Henn, V., Yonekawa, Y., Bauer, C., and Gassmann, M. (1996). Erythropoietin gene expression in human, monkey and murine brain. Eur. J. Neurosci. 8:666–676.
Masuda, S., Nagao, M., Takahata, K., Konishi, Y., Gallyas, F., Jr., Tabira, T., and Sasaki, R. (1993). Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J. Biol. Chem. 268:11208–11216.
McGlashan, T.H., and Hoffman, R.E. (2000). Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 57:637–648.
Mielke, R., Moller, H.J., Erkinjuntti, T., Rosenkranz, B., Rother, M., and Kittner, B. (1998). Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: Overview of phase I and phase II clinical trials. Alzheimer Dis. Assoc. Disord. 12(Suppl. 2):S29–S35.
Morishita, E., Masuda, S., Nagao, M., Yasuda, Y., and Sasaki, R. (1997). Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76:105–116.
Nakano, T., Kodama, H., and Honjo, T. (1996). In vitro development of primitive and definitive erythrocytes from different precursors. Science 272:722–724.
Parsa, C.J., Matsumoto, A., Kim, J., Riel, R.U., Pascal, L.S., Walton, G.B., Thompson, R.B., Petrofski, J.A., Annex, B.H., Stamler, J.S., and Koch, W.J. (2003). A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 112:999–1007.
Prass, K., Scharff, A., Ruscher, K., Lowl, D., Muselmann, C., Victorov, I., Kapinya, K., Dirnagl, U., and Meisel, A. (2003). Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34:1981–1986.
Ruscher, K., Freyer, D., Karsch, M., Isaev, N., Megow, D., Sawitzki, B., Priller, J., Dirnagl, U., and Meisel, A. (2002). Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J. Neurosci. 22:10291–10301.
Sakanaka, M., Wen, T.C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., and Sasaki, R. (1998). In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. U.S.A 95:4635–4640.
Sasaki, R., Masuda, S., and Nagao, M. (2001). Pleiotropic functions and tissue-specific expression of erythropoietin. News Physiol. Sci. 16:110–113.
Shingo, T., Sorokan, S.T., Shimazaki, T., and Weiss, S. (2001). Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J. Neurosci. 21:9733–9743.
Sirén, A.-L., and Ehrenreich, H. (2001). Erythropoietin—a novel concept of neuroprotection. Eur. Arch. Psychiatry Clin. Neurosci. 251:179–184.
Sirén, A.L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., Mennini, T., Heumann, R., Cerami, A., Ehrenreich, H., and Ghezzi, P. (2001b). Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci U.S.A. 98:4044–4049.
Sirén, A.-L., Knerlich, F., Poser, W., Gleiter, C., Brück, W., and Ehrenreich, H. (2001a). Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 101:271–276.
Stuckmann, I., Evans, S., and Lassar, A.B. (2003). Erythropoietin and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. Dev. Biol. 255:334–349.
Thompson, P.M., Vidal, C., Giedd, J.N., Gochman, P., Blumenthal, J., Nicolson, R., Toga, A.W., and Rapoport, J.L. (2001). From the Cover: Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 98:11650–11655.
Tramontano, A.F., Muniyappa, R., Black, A.D., Blendea, M.C., Cohen, I., Deng, L., Sowers, J.R., Cutaia, M.V., and El-Sherif, N. (2003). Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun. 308:990–994.
van Praag, H., Schinder, A.F., Christie, B.R., Toni, N., Palmer, T.D., and Gage, F.H. (2002). Functional neurogenesis in the adult hippocampus. Nature 415:1030–1034.
Villa, P., Bigini, P., Mennini, T., Agnello, D., Laragione, T., Cagnotto, A., Viviani, B., Marinovich, M., Cerami, A., Coleman, T.R., Brines, M., and Ghezzi, P. (2003). Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med. 198:971–975.
Wu, H., Lee, S.H., Gao, J., Liu, X., and Iruela-Arispe, M.L. (1999). Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126:3597–3605.
Yu, X., Shacka, J.J., Eells, J.B., Suarez-Quian, C., Przygodzki, R.M., Beleslin-Cokic, B., Lin, C.S., Nikodem, V.M., Hempstead, B., Flanders, K.C., Costantini, F., and Noguchi, C.T. (2002). Erythropoietin receptor signalling is required for normal brain development. Development 129:505–516.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ehrenreich, H., Aust, C., Krampe, H. et al. Erythropoietin: Novel Approaches to Neuroprotection in Human Brain Disease. Metab Brain Dis 19, 195–206 (2004). https://doi.org/10.1023/B:MEBR.0000043969.96895.3c
Issue Date:
DOI: https://doi.org/10.1023/B:MEBR.0000043969.96895.3c